Afqlir is indicated to treat various retinal diseases, including neovascular age-related macular degeneration (nAMD) ...

Sandoz's approval of Afqlir highlights their commitment to affordable, effective treatment options for retinal diseases.

Splicing accuracy enhanced This process is crucial for the life of the cell. "The spliceosome is composed of multiple components that secure production of functional proteins controlling cellular life ...

The study sheds light on how specific mutations may lead to the retinal disease retinitis pigmentosa. Importantly, these findings could also open the door to new diagnostic tests and treatments for a ...

The Healthcare Private Equity team has advised Retina Consultants of America (RCA) and Webster Equity Partners in the sale of ...

"I am thrilled to further strengthen and enrich Ocular's senior leadership team with the appointment of Namrata as Chief ...

Cataracts are one of the main eye disorders that can affect diabetic patients' eyesight, along with diseases including ...

AlloVir has entered into a definitive agreement for the acquisition of the complete outstanding shares of Kalaris ...

The Korea Research Institute of Standards and Science (KRISS) announced that they have developed an advanced disease ...

Ocular Therapeutix, Inc. (NASDAQ: OCUL, "Ocular", the "Company"), a biopharmaceutical company committed to improving vision in the real world through ...

Sandoz remains committed to accelerating patient access by strengthening its biosimilar portfolio, reinforcing global and European leadership ...

A delay in the FDA decision for NT-501 could leave those with macular telangiectasia (MacTel) without any form of treatment ...